Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer

Summary

Regorafenib is a valuable treatment option for metastatic colorectal cancer patients who have progressed after prior standard treatments. Prior progression-free survival data suggest that there could be a distinct subgroup of patients that may benefit from regorafenib. The aim of this study is to identify predictive biomarker of regorafenib in terms of its efficacy.

Timeline

Start

2013-10

Primary completion

2015-06

Completion

2016-05

Drugs

Indications